Background: Drug provocation is the "Gold Standard" in drug allergy investigation. Recent studies suggest that a negative drug provocation on first dose should be followed by a prolonged provocation over several days.
Objective: To evaluate drug allergy investigations on the basis of drug provocation, including prolonged provocation.
Methods: Data from adult patients investigated for drug allergy in a Danish Allergy Clinic during the period 2010 to 2014 were entered into a database. Data included clinical details and results of provocations with suspected culprit drug (for penicillins performed only in specific IgE-negative patients). If provocation was negative on first dose, treatment was continued for 3 to 10 days.
Results: A total of 1,913 provocations were done in 1,659 patients, median age 46 years, of whom 1,237 (74.6%) were females. Drugs investigated were antibiotics, 1,776 (92.8%), of which 1,590 (89.5%) were penicillins; analgesics, 59 (3.1%); local anesthetics, 33 (1.7%); and other drugs, 45 (2.4%). In total, 211 of 1,913 (11.0%) provocations were positive. Causes were antibiotics, 198 (93.8%), of which 167 (84.3%) were penicillins; analgesics, 7 (3.3%); local anesthetics, 0; and other drugs, 6 (2.8%). Only 43 (20.4%) provocations were positive on first dose, whereas 95 (45.0%) turned positive more than 3 days later.
Conclusions: Only 11.0% of the provocations were positive. Importantly, only 1 of 5 patients tested positive on the first dose, indicating that prolonged exposure should always be considered when drug provocation is included in allergy investigations. Most provocations were with penicillins, reflecting the pattern of antibiotic use in Denmark, which differs from that in other countries, especially outside Northern Europe.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jaip.2017.02.024 | DOI Listing |
Allergol Immunopathol (Madr)
January 2025
Pediatric Allergy and Pulmonology Unit, Children's University Hospital Reina Sofia, Cordoba, Spain;
Drug-induced enterocolitis syndrome (DIES), little known due to its recent description, is analogous to food protein-induced enterocolitis syndrome (FPIES). Both processes are more frequent in pediatric age and share diagnostic criteria, the main one being the appearance of persistent vomiting 1-4 hours after ingestion of the drug or food, in the absence of IgE-mediated allergy symptoms.
View Article and Find Full Text PDFAllergy
January 2025
St John's Institute of Dermatology, Guy's Hospital, London, UK.
Background: This study compared the therapeutic equivalence of CT-P39 (an omalizumab biosimilar) and EU-approved reference omalizumab (ref-OMA) in patients with chronic spontaneous urticaria.
Methods: This double-blind, randomized, active-controlled Phase 3 study (NCT04426890) included two 12-week treatment periods (TPs). In TP1, patients received CT-P39 300 mg, ref-OMA 300 mg, CT-P39 150 mg, or ref-OMA 150 mg.
Alzheimers Dement
December 2024
Columbia University Irving Medical Center, New York, NY, USA.
For Alzheimer's disease (AD), there are currently two FDA-approved agents developed as disease-modifying treatments. Approval of lecanemab (Leqembi®) in 2023, via accelerated approval mechanism, followed by traditional approval accompanied by medical coverage decision by the Center for Medicare Services, has resulted in increasing use of this anti-amyloid monoclonal antibody, demonstrated in 18-month long clinical trials to slow Alzheimer's disease. Despite a broad package insert (with only contraindication product severe hypersensitivity), nationwide prescriptions have been reportedly affected by concerns regarding drug eligibility, monitoring, and whether real-world experience would mirror clinical trial data.
View Article and Find Full Text PDFBackground: We aim to repurpose the widely used adjuvant and immunomodulator Alhydrogel at a specific dose and schedule (AD04) as a disease-modifying treatment for mild Alzheimer's disease (AD). AD04 is a potent adjuvant commonly used in vaccines and allergy immunotherapies to augment the magnitude and durability of the immune response. Our preliminary data come from a clinical Phase 2 study in which AD04 served as a control arm.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Soleo Health, Frisco, TX, USA.
Background: The approval of anti-amyloid monoclonal antibodies (mAbs) provides a novel approach to the treatment of Alzheimer's disease. Infusions in alternative sites of care can benefit the patient financially and logistically, but coverage is largely payor dependent. The purpose of this study is to describe observations from this national complex specialty pharmacy around the safety of anti-amyloid mAb infusions in alternative sites of care, including the home.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!